In another in vivo study of a BC mouse model, treatment with anti-CTLA-4 antibody delayed tumor growth, and anti-CTLA-4 antibody plus matrix metalloproteinase inhibitor therapy reduced the percentage of Tregs, Th17 cells, and MDSCs in tumors compared with the control group.295. This evidence concerns the gene CTLA4 and neoplasm.